SCHEMBL2429665

SCHEMBL2429665

CC(C)(C)OC(=O)c1ncc[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 1/20 0.39
GABRA1 P14867 3/20 0.35
GABRG2 P18507 3/20 0.35
GABRB3 P28472 3/20 0.35
GABRA5 P31644 3/20 0.35
GABRA3 P34903 3/20 0.35
GABRA2 P47869 3/20 0.35
GABRA4 P48169 3/20 0.35
GABRA6 Q16445 3/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRE P78334 1/20 0.35
GABRG1 Q8N1C3 1/20 0.35
GABRG3 Q99928 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Imidazole SCHEMBL28321978 0.88 NPC1 (0.38) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL9139120 0.84 NPC1 (0.42) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL5838309 0.82 NPC1 (0.42) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL4636002 0.82 NPC1 (0.40) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL262815 0.79
Ornithine SCHEMBL3801714 0.78 GSR (0.39) NPC1RAB9A
SCHEMBL5164159 0.78 NPC1 (0.40) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL31229951 0.78 NPC1 (0.47) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL6858144 0.77 RAB9A (0.39) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL23367084 0.75 L3MBTL1 (0.41) NPC1RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3494162-A1 NON-TIN CATALYST FOR CURING ALKOXYSILYL-CONTAINING POLYMER Momentive Performance Materials Inc. (US) 2019-06-12 EP claimed
WO-2018049375-A1 NON-TIN CATALYST FOR CURING ALKOXYSILYL-CONTAINING POLYMER MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2018-03-15 WO claimed
WO-2008082224-A1 WATER-SOLUBLE PHOTOINITIATORS INKTEC CO., LTD. (KR) 2008-07-10 WO claimed
EP-1218338-A1 PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES ABBOTT LABORATORIES (US) 2002-07-03 EP claimed
WO-2001027074-A1 PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES ABBOTT LABORATORIES (US) 2001-04-19 WO claimed
EP-0211580-A2 Renin inhibiting polypeptides and intermediates therefor PFIZER INC. (US) 1987-02-25 EP claimed
US-20250340567-A1 Next Generation Synthetic Transcription Factors WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2025-11-06 US disclosed
US-20250282621-A1 CARBON NANOTUBE COMPOSITE COMPRISING MECHANICAL L IGANDS NANOCORE APS (DK) 2025-09-11 US disclosed
US-20250145731-A1 LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE REMEGEN CO., LTD. (CN) 2025-05-08 US disclosed
US-12208088-B2 Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof GENENTECH, INC. (US) 2025-01-28 US disclosed
US-12195552-B2 Linker for antibody-drug conjugates and its use REMEGEN CO., LTD. (CN) 2025-01-14 US disclosed
EP-3868409-B1 THIOPHENOL-MALEIMIDE AND BROM-MALEIMIDE DERIVATIVES AS LINKER FOR ANTIBODY-DRUG CONJUGATES (ADC) FOR TREATING TUMORS REMEGEN CO LTD (CN) 2024-07-17 EP disclosed
EP-4363373-A1 CARBON NANOTUBE COMPOSITE COMPRISING MECHANICAL LIGANDS Nanocore ApS (DK) 2024-05-08 EP disclosed
US-4857513-A Diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISIWA PHARMACEUTICAL CO., LTD. (JP) 1989-08-15 US disclosed
EP-0307837-A2 Renin-inhibiting peptidyl heterocycles ABBOTT LABORATORIES (US) 1989-03-22 EP disclosed
US-4729985-A Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues PFIZER INC. (US) 1988-03-08 US disclosed
US-4725680-A AMINATION, CLEAVAGE, NEUTRALIZATION SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1988-02-16 US disclosed
EP-0243173-A2 New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-10-28 EP disclosed
EP-0212903-A2 Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues PFIZER INC. (US) 1987-03-04 EP disclosed
CN-85101512-A PROCESS FOR PREPARING CARBAMIC ACID DERIVATIVES 1987-01-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12208088-B2 Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof HIPK1, NEK1, HIPK2 NPC1 1141/4885RAB9A 2380/4885ALDH1A1 2398/4885
US-12195552-B2 Linker for antibody-drug conjugates and its use PA2G4, IGSF11, FCGRT NPC1 4648/4885RAB9A 3867/4885ALDH1A1 321/4885
US-20250340567-A1 Next Generation Synthetic Transcription Factors ZFX, RUNX1, JUN NPC1 3622/4885RAB9A 4063/4885ALDH1A1 4799/4885
US-20250145731-A1 LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE PA2G4, IGSF11, FCGRT NPC1 4648/4885RAB9A 3867/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.